Trevi Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
TRVI$14.91-2.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statem ents of Cash Flows
(Amounts in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(47,911) | $(29,065) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 3,588 | 2,247 |
| Operating lease right-of-use assets | 460 | 377 |
| Depreciation and amortization | 147 | 123 |
| Accretion of available-for-sale marketable securities, net | (1,367) | (2,125) |
| Write off of deferred offering costs | — | 390 |
| Accretion/accrual of term loan discounts and debt issuance costs | — | 180 |
| Loss on disposal of property, equipment and leasehold improvements | — | 10 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 2,659 | (2,850) |
| Accrued expenses and other liabilities | 2,563 | 52 |
| Accounts payable | 1,605 | (1,049) |
| Net cash used in operating activities | (38,256) | (31,710) |
| Investing activities: | ||
| Proceeds from maturities of available-for-sale marketable securities | 76,970 | 69,497 |
| Purchases of available-for-sale marketable securities | (98,463) | (9,932) |
| Purchases of property, equipment and leasehold improvements | (35) | (137) |
| Net cash (used in) provided by investing activities | (21,528) | 59,428 |
| Financing activities: | ||
| Proceeds from offering, net of commissions | 47,000 | — |
| Proceeds from at-the-market sales, net of commissions | 14,146 | 1,710 |
| Proceeds from exercises of stock options | 394 | 74 |
| Proceeds from employee stock purchase plan | 70 | 68 |
| Payments of finance lease | (126) | (95) |
| Repayments of term loan, term loan final fee and prepayment premium | — | (9,409) |
| Payments of offering costs | — | (258) |
| Net cash provided by (used in) financing activities | 61,484 | (7,910) |
| Net increase in cash and cash equivalents | 1,700 | 19,808 |
| Cash and cash equivalents at beginning of period | 32,397 | 12,589 |
| Cash and cash equivalents at end of period | $34,097 | $32,397 |
| Supplemental disclosure of cash flow information: | ||
| Interest paid | $(4) | $(331) |
| State research tax credits exchanged for cash | $32 | $55 |
| Supplemental disclosure of non-cash financing activities: | ||
| Offering costs included in accrued expenses | $233 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.